Microfibrillar Collagen in Surgical Hemostasis

Microfibrillar collagen is a surgical material derived from purified bovine (cow) hide collagen, processed into fine fibers that trigger the body’s natural clotting response when pressed against a bleeding wound. It has been used in operating rooms since the mid-1970s, primarily as a topical hemostat, meaning a material applied directly to tissue surfaces to help stop bleeding during surgery. Though its core function sounds simple, microfibrillar collagen occupies a surprisingly complicated space in modern surgery, with distinct advantages over other hemostatic agents in some settings and real limitations in others.

How It Actually Stops Bleeding

When microfibrillar collagen contacts blood, it works by physically attracting platelets to its surface. The collagen fibers provide a rough, adhesive scaffold that mimics what happens when your body’s own collagen is exposed at an injury site. Platelets stick to the fibers, become activated, and release chemical signals that recruit more platelets. This cascade of adhesion and aggregation builds a stable clot directly at the bleeding surface.

The fibrillar structure of the collagen matters more than you might expect. Research on how platelets interact with different forms of collagen has shown that the banded, fibrillar arrangement supports platelet adhesion through multiple receptor pathways simultaneously. When one receptor pathway is blocked, platelets can still attach to fibrillar collagen through alternative receptors, something that does not work as well with non-fibrillar collagen preparations. The fibrillar structure also promotes the binding of von Willebrand factor and other blood proteins from plasma, which further accelerates clot formation under the shear stress of flowing blood.¹ This redundancy in clotting pathways is part of why microfibrillar collagen works even in situations where other agents struggle.

Unlike some surgical hemostats that rely on chemical reactions or clotting factor supplements, microfibrillar collagen works through direct platelet activation. It has a neutral pH, which means it does not irritate surrounding tissue the way oxidized cellulose products can.² That neutral pH is a meaningful clinical advantage in delicate tissue environments like the brain or spinal cord, where even mild chemical irritation can cause problems.

What It Looks Like and How Surgeons Apply It

Microfibrillar collagen is manufactured as a sterile, porous, water-insoluble material prepared as a partial hydrochloric acid salt of purified bovine corium collagen. The first product, marketed as Avitene, was approved by the FDA in 1976 in a loose flour-like form. Since then, the material has been developed into multiple configurations including sheets, sponges, and pre-rolled applicators designed for specific surgical scenarios.³

An early naming quirk is worth mentioning. Some older publications refer to the material as “microcrystalline” collagen, but the FDA’s preferred term is “microfibrillar,” reflecting the actual fibrous structure of the processed material rather than a crystalline one.⁴

The flour form can be applied directly to a bleeding surface, but it has practical downsides: it is light, can scatter, and does not always stay where you put it in a wet surgical field. To address this, flowable formulations have been developed by mixing the microfibrillar collagen flour with saline. In preclinical testing using a liver injury model in pigs, the flowable preparation provided more precise application and more uniform coverage compared to the dry flour. Both the flowable and dry forms achieved complete hemostasis in every animal tested, while plain gauze stopped bleeding in only about 8 to 42 percent of cases. The two collagen preparations also showed comparable tissue healing out to 120 days.⁵

For minimally invasive surgery, pre-rolled sheets of microfibrillar collagen have been designed to fit through standard laparoscopic ports. Testing in laparoscopic liver biopsies in a porcine model confirmed the material maintained its hemostatic properties when delivered this way.⁶ The ability to use the material in keyhole procedures significantly expanded its practical reach beyond open surgery.

Combination Products

Microfibrillar collagen also serves as a structural backbone in combination hemostatic products. One such formulation, marketed as CoStasis, blends microfibrillar collagen with bovine thrombin and the patient’s own plasma to create a sprayable liquid composite. The collagen provides the adhesive scaffold for platelet attachment while the thrombin directly activates the clotting cascade, and the autologous plasma supplies fibrinogen and other clotting factors. This combination was tested in a randomized controlled trial across multiple surgical indications.⁷ The idea is to stack multiple hemostatic mechanisms for situations where any single agent might not be enough.

In interventional radiology, microfibrillar collagen paste has been used to seal the needle track after transhepatic procedures, where a catheter is passed through the liver. A study comparing microfibrillar collagen paste to coils and to a coil-plus-gelatin-sponge combination for closing the liver tract after islet cell transplants in patients on anticoagulation medications found all three approaches similarly effective.⁸ That the collagen paste held its own even in patients on blood thinners is a meaningful data point, since anticoagulated patients represent one of the most challenging hemostasis scenarios in clinical practice.

How It Stacks Up Against Other Hemostats

Surgeons have several classes of topical hemostatic agents to choose from, and the comparative data shows microfibrillar collagen performs well in some settings and less impressively in others. The picture depends heavily on the type of bleeding and the anatomical location.

In a randomized trial comparing collagen-based hemostats to oxidized cellulose, the collagen achieved hemostasis significantly faster and required less material. Surgeons also rated the collagen substantially easier to use.⁹ A study in high-risk cardiac surgery found that patients who received microfibrillar collagen had considerably less chest tube drainage over the first 24 hours compared to those who received oxidized cellulose: roughly 370 mL versus 570 mL. The difference was most pronounced in the first three hours after surgery, when blood loss in the collagen group was nearly half that of the cellulose group.¹⁰

The picture is less favorable when microfibrillar collagen is compared to gelatin-based products for bone bleeding. In a quantitative study of hemostasis during hip surgery, gelatin paste reduced bleeding by about 85 percent over a three-minute interval, gelatin sponge soaked in thrombin reduced it by about 75 percent, and microfibrillar collagen reduced it by about 47 percent. With no hemostatic agent at all, bleeding dropped by only about 11 percent on its own.¹¹ Microfibrillar collagen clearly beat doing nothing, but was notably outperformed by gelatin preparations in this particular context. Bone surfaces present a different hemostatic challenge than soft tissue because the bleeding comes from rigid channels in the bone itself, which cannot be compressed.

These mixed results highlight something important: there is no single best hemostat for all situations. Surgeons typically choose based on the tissue type, the severity of bleeding, and practical handling characteristics. Microfibrillar collagen tends to shine in soft-tissue bleeding where its neutral pH and platelet-activating mechanism are assets, while gelatin-based products may work better for bony surfaces.

What Happens to It After Surgery

Microfibrillar collagen is fully absorbable. The body breaks it down using collagenases, the same family of enzymes that remodel natural collagen throughout your tissues. Complete absorption typically occurs within 8 to 12 weeks.¹² A systematic review of the material notes absorption in less than 90 days.¹³ This means the material does its job during the critical early hours and days of healing, then gradually disappears, leaving no permanent foreign body behind.

That said, the degradation period is not entirely uneventful. In a rat neurosurgical model, microfibrillar collagen was associated with granuloma formation, a localized clumping of immune cells around the foreign material, similar to what was seen with gelatin-based sealants.¹⁴ In most patients this foreign-body reaction is microscopic and clinically silent, but it occasionally causes real problems.

Complications Worth Knowing About

The most talked-about complication is the formation of a granulomatous mass, where the body’s immune response to residual microfibrillar collagen creates a visible lump that can mimic a tumor or infection on imaging. In spinal surgery, this has led to diagnostic confusion. One reported case involved a patient who developed nerve compression symptoms after disc surgery. A second operation ten days later revealed that the nerve root was stuck to a granulomatous mass composed mainly of residual microfibrillar collagen hemostat material. On imaging, the mass looked like a recurrent disc herniation.¹⁵ The lesson for surgeons and radiologists is that when a mass appears on postoperative imaging, microfibrillar collagen granuloma belongs on the list of possibilities alongside the more obvious diagnoses.

In pediatric neurosurgery, a case series documented necrotizing granulomatous inflammation developing after craniotomies where microfibrillar collagen had been used. On MRI, these reactions most commonly triggered concern about tumor recurrence or abscess. Pathological examination revealed a distinctive inflammatory pattern rich in eosinophils, a type of white blood cell associated with allergic reactions. Multiple authors have suggested an allergy-based mechanism for these reactions, though the exact cause remains debated.¹⁶ These events are rare, but when they do occur, they can lead to unnecessary second surgeries if the surgical team does not consider hemostatic material as the culprit.

The Infection Question

One of the more unsettling findings in the older literature concerns infection risk. In an experimental wound model, when wounds were treated with microfibrillar collagen before being contaminated with bacteria, 90 percent developed infections. There was no dose-dependent relationship either: even small amounts of the material promoted infection.¹⁷ The study found that oxidized cellulose also promoted infection, though with a dose-related pattern that microfibrillar collagen lacked.

This finding makes biological sense. Any foreign material left in a wound gives bacteria a surface to colonize, and the collagen’s porous structure may provide sheltered niches where bacteria can multiply before the immune system can reach them. In clinical practice, this means surgeons generally try to use the minimum amount of hemostatic material needed and remove excess material once hemostasis is achieved, particularly in contaminated or potentially contaminated wounds. Still, these are animal model findings, and the real-world infection rate attributable specifically to microfibrillar collagen use in humans is harder to pin down because so many other factors influence surgical site infection.

Vascular Embolization and Microvascular Risks

The fine, particulate nature of microfibrillar collagen that makes it effective as a topical hemostat also creates a hazard if particles enter the bloodstream. Microfibrillar collagen has been explored as an agent for transcatheter embolization, where it is deliberately injected into blood vessels to block them. While this can be therapeutically useful for stopping internal bleeding, the main disadvantage is that if normal tissues are inadvertently embolized, ischemic complications can result, meaning healthy tissue loses its blood supply and dies.¹⁸

The severity of this risk was illustrated in a canine research model studying cerebral infarction. When microfibrillar collagen was injected into the carotid artery of dogs, the resulting neurological damage ranged from mild weakness on one side of the body to death, depending on the dose delivered. In one series of ten dogs receiving a standardized dose, seven developed a survivable stroke, two died, and one showed no clinical effect at all.¹⁹ These findings, while derived from a deliberately extreme scenario, underscore why surgeons must be careful to apply microfibrillar collagen only to tissue surfaces and avoid situations where particles could be carried into the circulation, especially near large vessels or in highly vascular surgical fields.

Where Neurosurgeons Rely on It

Neurosurgery is one of the specialties where microfibrillar collagen has carved out a particularly strong niche. The neutral pH that distinguishes it from oxidized cellulose is especially valued in and around the brain and spinal cord, where acidic materials could damage neural tissue. Microfibrillar collagen hemostats have been used in neurosurgery since the 1970s, making them one of the longest-standing hemostatic agents in the neurosurgical toolkit.²⁰

The irony is that neurosurgery is also where some of the most concerning complications have been documented, as noted with the granulomatous reactions in both adult and pediatric patients. The brain and spine are enclosed spaces where even a small mass can cause symptoms. A granuloma that would be clinically invisible in an abdominal cavity can compress a nerve root or mimic a brain tumor when it develops near the spinal cord or within the cranial vault. This does not mean the material is too dangerous for neurosurgical use; it means postoperative imaging needs to be interpreted with the knowledge that microfibrillar collagen was placed at the surgical site.

Beyond Bovine Sources

Nearly all commercially available microfibrillar collagen hemostats are derived from cows, which raises two concerns that have driven research into alternatives. The first is immunogenicity. While serious allergic reactions to bovine collagen hemostats are uncommon, the material is a foreign animal protein, and the eosinophil-rich inflammatory reactions seen in some case reports suggest that at least some patients mount an immune response to it. The second concern is the theoretical risk of transmitting bovine-origin infections, including prion diseases.

Marine-sourced collagens from fish, jellyfish, and sea cucumber are reported to produce lower immune responses compared to mammalian sources and carry reduced concerns about prion-related diseases, though these observations vary depending on species, processing methods, and how the collagen is used.²¹ Recombinant technologies represent an even more radical departure. Using microbial and eukaryotic expression systems, researchers can now produce human-like collagens with tailored properties.²²

A recombinant collagen hemostatic sponge has already been tested and shown to be fully biodegradable in animal models, without stimulation, sensitization, acute toxicity, blood cell destruction, or obvious immune rejection.²³ If these results hold up in human trials, recombinant hemostats could eliminate both the immunogenicity and the animal-sourcing concerns simultaneously. They would also offer the possibility of engineering the collagen fiber structure to optimize platelet activation, potentially improving on the somewhat inconsistent hemostatic performance that current bovine products show across different bleeding scenarios.

Tissue Engineering Applications

Beyond stopping bleeding, microfibrillar collagen is finding a second life as a building material for tissue engineering. Because it provides a three-dimensional fibrous scaffold that cells can attach to and grow within, researchers have explored it as a substrate for growing replacement tissues outside the body.

One research group used microfibrillar type I collagen combined with chondroitin sulfate, a naturally occurring sugar chain, to create scaffolds for heart valve tissue engineering. When human umbilical cord blood endothelial progenitor cells were seeded into these scaffolds, the cells showed significantly greater metabolic activity at both 7 and 14 days compared to controls, indicating that the cells were not just surviving but actively proliferating within the collagen matrix.²⁴ This is still laboratory-stage work, far from clinical application, but it illustrates how the same properties that make microfibrillar collagen effective as a hemostat, its biocompatibility and its ability to support cell adhesion, also make it attractive as a scaffold for growing living tissues. The jump from surgical tool to tissue engineering platform is a natural one, even if the practical applications remain years away.